287403-15-0

Usage

Uses

Used in Pharmaceutical Industry:
[(4-FLUORO-BENZENESULFONYL)-METHYL-AMINO]-ACETIC ACID is used as a building block for the synthesis of more complex molecules, particularly in the development of new drugs. Its unique chemical structure allows for the creation of a wide range of pharmaceutical compounds with diverse therapeutic applications.
Used in Research:
In the field of research, [(4-FLUORO-BENZENESULFONYL)-METHYL-AMINO]-ACETIC ACID serves as an important compound for studying the properties and interactions of benzenesulfonamides. Its chemical structure provides valuable insights into the design and synthesis of novel molecules with potential applications in various fields, including medicine, biology, and materials science.
Used in Drug Development:
[(4-FLUORO-BENZENESULFONYL)-METHYL-AMINO]-ACETIC ACID is used as a key intermediate in the development of new drugs, particularly those targeting specific biological pathways or receptors. Its unique chemical properties enable the creation of molecules with enhanced potency, selectivity, and pharmacokinetic profiles, ultimately leading to more effective treatments for various diseases and conditions.
Used in Chemical Synthesis:
As a versatile building block, [(4-FLUORO-BENZENESULFONYL)-METHYL-AMINO]-ACETIC ACID is employed in the synthesis of a variety of chemical compounds, including those with potential applications in the fields of agriculture, materials science, and environmental science. Its unique structure allows for the development of novel compounds with improved properties and performance characteristics.

Upstream product

• 287407-07-2 tert-butyl 2-(4-fluoro-N-methylphenylsulfonamido)acetate 
• 287403-14-9 ethyl 2-(4-fluoro-N-methylphenylsulfonamido)acetate 
• 349-88-2 4-Fluorobenzenesulfonyl chloride 

Downstream Products

• 1610505-73-1 2-[(4-fluorobenzenesulfonyl)methylamino]-N-[4-(4-trifluoromethylphenyl)morpholin-2-ylmethyl]acetamide 
• 1590397-03-7 2-[(4-fluorobenzenesulfonyl)(methyl)amino]-N-[6-(4-trifluoromethylphenyl)pyrimidin-4-ylmethyl]acetamide 
• 1590396-94-3 2-[(4-fluorobenzenesulfonyl)-(methyl)amino]-N-(4-fluoro-4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590396-93-2 2-[(4-fluorobenzenesulfonyl)(methyl)amino]-N-(5-fluoro-4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590396-92-1 2-[(4-fluorobenzenesulfonyl)(methyl)amino]-N-(4'-trifluoromethylbiphenyl-4-ylmethyl)acetamide 
• 1590396-91-0 2-[(4-fluorobenzenesulfonyl)-methylamino]-N-(2-fluoro-4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590396-90-9 2-[(4-fluorobenzenesulfonyl)(methyl)amino]-N-(6-fluoro-4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590397-25-3 2-[(4-fluorobenzenesulfonyl)(methyl)amino]-N-(5-methoxy-4'-trifluoromethylbiphenyl-3-ylmethyl)acetamide 
• 1590397-23-1 2-[(4-fluorobenzenesulfonyl)(methyl)amino]-N-[3-(5-trifluoromethylpyridin-2-yl)benzyl]acetamide 

Relevant academic research and scientific papers

Design, synthesis, and in?vitro evaluation of BP-1-102 analogs with modified hydrophobic fragments for STAT3 inhibition

Twelve novel analogs of STAT3 inhibitor BP-1-102 were designed and synthesised with the aim to modify hydrophobic fragments of the molecules that are important for interaction with the STAT3 SH2 domain. The cytotoxic activity of the reference and novel co

Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia

The HDAC inhibitor 4-tert-butyl-N-(4-(hydroxycarbamoyl)phenyl)benzamide (AES-350, 51) was identified as a promising preclinical candidate for the treatment of acute myeloid leukemia (AML), an aggressive malignancy with a meagre 24% 5-year survival rate. Through screening of low-molecular-weight analogues derived from the previously discovered novel HDAC inhibitor, AES-135, compound 51 demonstrated greater HDAC isoform selectivity, higher cytotoxicity in MV4-11 cells, an improved therapeutic window, and more efficient absorption through cellular and lipid membranes. Compound 51 also demonstrated improved oral bioavailability compared to SAHA in mouse models. A broad spectrum of experiments, including FACS, ELISA, and Western blotting, were performed to support our hypothesis that 51 dose-dependently triggers apoptosis in AML cells through HDAC inhibition.

Androgen receptor antagonist as well as preparation method and application thereof

The invention relates to an androgen receptor antagonist as well as a preparation method and an application thereof. The androgen receptor antagonist is a compound shown as the general formula (I) inthe description or a pharmaceutically acceptable salt of the compound (R1, R2, R3 and R4 in the general formula are defined in the description).

NOVEL ACETAMIDE DERIVATIVES AS TRP CHANNEL ANTAGONISTS

The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R3, X and Y are as defined as in the description and in the claims. The compound of formula (I) can be used as a medicament for therapy and/or prophylaxis in a mammal of an inflammatory disease or disorder, and in particular to Transient Receptor Potential (TRP) channel antagonists.

ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS

Compound of the formula (B) are useful in treating disease conditions mediated by TNF- alpha , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.